A Polygenic Risk Score for Prostate Cancer Risk Prediction
Menée à partir de données portant sur 655 hommes ayant bénéficié d'une biopsie prostatique (âge médian : 63 ans ; niveau médian du PSA : 5,3 ng/ml), cette étude évalue, par rapport à un outil clinique en ligne basé sur 6 paramètres (âge, origine ethnique, niveau du PSA, résultats de l'examen par toucher rectal et de la biopsie, antécédents familiaux), la performance du système de score polygénique PRS 269 pour détecter un cancer de la prostate
Prostate cancer screening instruments frequently result in men undergoing prostate biopsies that find either clinically insignificant (grade group [GG], 1) cancer or no cancer. A polygenic risk score measures the burden of risk-associated single-nucleotide polymorphisms that an individual carries, and there is interest in using these scores to improve risk prediction for prostate cancer. Although polygenic risk scores have been associated with prevalent and incident disease, prior studies have shown that they do not improve risk prediction for aggressive prostate cancers with the potential to be fatal. In this study, we compared the polygenic risk score (PRS269) as defined by Conti et al to the Prostate Biopsy Collaborative Group risk calculator, a clinical tool that computes the probabilities of finding (1) any cancer and (2) high-grade (GG ≥2) cancer on biopsy results in men undergoing a first prostate biopsy.
JAMA Internal Medicine , résumé, 2022